Tirzepatide for Post-Menopause Weight Gain
GLP-1 medications help overcome hormonal metabolic slowdown. Tirzepatide (Zepbound/Mounjaro) is a dual GLP-1/GIP receptor agonist with 20-22% average body weight loss — the highest of any GLP-1 medication.
How Tirzepatide Helps with Post-Menopause Weight Gain
Tirzepatide targets both GLP-1 and GIP receptors for enhanced appetite control and metabolic effects. This dual mechanism produces the highest weight loss of any available GLP-1 medication. For patients with post-menopause weight gain, the significant weight loss translates to meaningful improvements in condition outcomes.
GLP-1 medications help overcome hormonal metabolic slowdown. The SURMOUNT-1 clinical trial demonstrated that tirzepatide at the highest dose produces an average weight loss of 22.5% of body weight over 72 weeks.
Clinical Evidence for Post-Menopause Weight Gain
Post-Menopause Weight Gain affects Affects most post-menopausal women. Tirzepatide's dual receptor mechanism provides particularly strong metabolic benefits that extend beyond weight loss, including improved insulin sensitivity, better lipid profiles, and reduced inflammation.
Tirzepatide Dosing for Post-Menopause Weight Gain
Tirzepatide is administered as a once-weekly subcutaneous injection. Treatment starts at 2.5mg and can increase to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg based on response and tolerability. Each dose increase occurs at 4-week intervals.
Cost of Tirzepatide for Post-Menopause Weight Gain
Compounded tirzepatide costs $199-449/month through telehealth providers. Brand-name Zepbound costs $1,100+/month without insurance. The higher cost compared to semaglutide may be justified by the greater average weight loss.